Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus
https://doi.org/10.14341/2072-0351-5675
Abstract
High prevalence of arterial hypertension and related cardiovascular complications dictates the necessity of preparations possessed of markedorganoprotective activity and good tolerability. The currently available data suggest advantages of iACE and ARB as preparations for the treatmentof cardiovascular diseases such as ability of iACE to improve clinical picture and outcome of therapy of cardiac insufficiency, left ventricle dysfunction,and myocardial infarction. Large-scale prospective studies demonstrated effectiveness of these agents in the treatment of CHD, stroke, diabetes, renalpathology and revealed their additional advantages attributable to inhibition of angiotensin II secretion other than those related to reduction of AP.These studies gave evidence of a more pronounced decrease in the frequency of cardiovascular events under effect of ARB in high-risk patients. However,protective action of ARB on the cardiovascular system compared with that of iACE and combination of ARB+iACE awaits an in-depth study.
About the Authors
Ivona Yanovna Yarek-Martynova
Endocrinology Research Centre, Moscow
Minara Shamkhalovna Shamkhalova
Endocrinology Research Centre, Moscow
References
1. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee // J. Hypertens. - 2003. - 21. - Р. 1011-1053.
2. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension // J. Hypertens. - 2007 - 25. - Р. 1105-1187.
3. Rippin J., Bain S.C., Barnet A.N. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. // J.Diabetes Compilcations. - 2002. - 16(3). - P. 195-200.
4. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Eng. J. Med. - 2008. - V358. - Р. 1547-1559.
5. TRANSCEND Investigators, Yusuf S., Teo K., Anderson C., Pogue J., Dyal L., Copland I., Schumacher H., Dagenais G., Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in highrisk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. - 2008. - V. 372. - Р. 1174-1183.
6. The Heart Outcomes Prevention Evaluation Study Investigators. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients // N. Engl. J. Med. - 2000. - 342. - Р. 145-153.
7. Mann J.F., Schmieder R.E., Dyal L. et al. Effect of telmisartan on renal outcomes: a randomized trial // Ann. Intern. Med. - 2009. - 151(1). - Р. 1-10.
8. Schmieder R.E., et al. Eur. Soc. Hypertension, 2009.
9. Verdecchia P., Sleight P., Mancia G. et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease // Circulation. - 2009. - 120(14). - Р. 1380- 1389.
10. Yusuf S., Diener H.C., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. - 2008. - 359. - Р. 1225-1237.
Review
For citations:
Yarek-Martynova I.Ya., Shamkhalova M.Sh. Organoprotecive effects of angiotensin II receptor blockers in patients with type 2 diabetes mellitus. Diabetes mellitus. 2010;13(2):58-61. (In Russ.) https://doi.org/10.14341/2072-0351-5675
Views:
1695
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
